Abbott’s Takedown Shakedown – an update
Following action from users, admins, healthcare staff and advocates, Abbott have responded on the takedown shenanigans. This seems to be a company statement that has […]
Abbott
Abbott’s Takedown Shakedown. No Libre no more
Over the past 48 hours, numerous Facebook groups across Europe that were unaffiliated with Abbott but provided “User group” services to Freestyle Libre users received […]
Waving the white flag? Medtronic partners with Abbott for CGM.
Breaking news in the world of Diabetes tech today saw Medtronic and Abbott share news of a partnership to provide Abbott CGM technology to Medtronic […]
When n=1 is not enough. An initial take on the Libre2 and Libre2 Plus comparison
As I mentioned a couple of weeks ago, I received a number of Libre2 and Libre2 Plus devices to try. So far, I’ve only used […]
Welcome to the Wild, Wild West: the CGM head-to-head study
In the past at Diabettech, we’ve talked about how the design of a CGM safety and accuracy study plays a big part in the results […]
A lesson in how not to roll out real-time CGM to an existing system
What impact does a botched rollout of an app update have on a CGM provider?
The art of CGM accuracy studies, part 2: The Freestyle Libre3
As I’m currently testing a Libre3, and have taken a look back at the various accuracy studies as a part of this to review MARD data, […]
Comparing the Libre2 and Dexcom G6 as RT-CGM using #WeAreNotWaiting software
The Libre2 has been available for some time now in both Germany and Norway, and is used by a reasonable number of loopers to drive […]
#FreestyleLibre & #MiaoMiao: Two weeks. What did I think?
After running with the FreeStyle Libre with the MiaoMiao as a CGM system for two weeks, I’ve drawn some conclusions from use, although there’s a […]
Death or profit: Flash, CGM and patient-centricity
As many people with T1D in the UK will know, there has been an ongoing dialogue between NHS England and the DVLA with respect to […]